E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers S > Headlines for Shire plc > News item
Published on 11/3/2006 in the Prospect News Biotech Daily.

Shire remains at hold for Jefferies

Shire Pharmaceuticals Group plc was reiterated at hold by Jefferies & Co. Inc. analyst Robin Campbell after strong ADHD results and the launch for Daytrana helped post solid figures for the third quarter. Campbell added that an approvable letter for NRP104 prolongs the wait, but not unexpectedly. Shares of the Basingstoke, England-based pharmaceutical company up 3.5p, or 0.36%, at 977p. (London: SHP)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.